Alex Toker

Affiliations: 
Harvard University, Cambridge, MA, United States 
Area:
Pathology, Cell Biology, Molecular Biology
Google:
"Alex Toker"

Children

Sign in to add trainee
Christian Dibble grad student
Whitney Henry grad student
Evan Lien grad student
Maria L. Mancini grad student
Sokha Nhek grad student 2009 Harvard
Jessica L. Fry grad student 2010 Harvard
Claudine V. Cohick grad student 2011 Harvard
Jessica A. Gasser grad student 2014 Harvard
Emilie Clement post-doc
Sivan Elloul post-doc
Sebastien Jauliac post-doc
Peter Storz post-doc
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Liu H, Paddock MN, Wang H, et al. (2020) The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple Negative Breast Cancer. Cancer Discovery
Geck RC, Foley JR, Murray Stewart T, et al. (2020) Inhibition of the polyamine synthesis enzyme ornithine decarboxylase sensitizes triple-negative breast cancer cells to cytotoxic chemotherapy. The Journal of Biological Chemistry
Guo J, Dai X, Laurent B, et al. (2019) AKT methylation by SETDB1 promotes AKT kinase activity and oncogenic functions. Nature Cell Biology
Toker A, Dibble CC. (2018) PI 3-Kinase Signaling: AKTing up inside the Cell. Molecular Cell. 71: 875-876
Lien EC, Ghisolfi L, Geck RC, et al. (2017) Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT. Science Signaling. 10
Liu H, Murphy CJ, Karreth FA, et al. (2017) Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discovery
Manning BD, Toker A. (2017) AKT/PKB Signaling: Navigating the Network. Cell. 169: 381-405
Lien EC, Dibble CC, Toker A. (2017) PI3K signaling in cancer: beyond AKT. Current Opinion in Cell Biology. 45: 62-71
Brown KK, Spinelli JB, Asara JM, et al. (2017) Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer. Cancer Discovery
Thomas C, Henry W, Cuiffo BG, et al. (2017) Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers. Science Signaling. 10
See more...